| 商品名称 | Pemetrexed Fresenius Kabi |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Carcinoma, Non-Small-Cell Lung;Mesothelioma |
|---|
| 通用名/非专利名称 | pemetrexed |
|---|
| 活性成分 | pemetrexed |
|---|
| 产品号 | EMEA/H/C/003895 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Authorised |
|---|
| ATC编码 | L01BA04 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | Yes |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2016/07/22 |
|---|
| 上市许可开发者/申请人/持有人 | Fresenius Kabi Deutschland GmbH |
|---|
| 人用药物治疗学分组 | Antineoplastic agents |
|---|
| 兽用药物治疗学分组 | |
|---|
| 审评意见日期 | 2016/05/26 |
|---|
| 欧盟委员会决定日期 | 2024/12/19 |
|---|
| 修订号 | 15 |
|---|
| 治疗适应症 | Malignant pleural mesothelioma Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Fresenius Kabi is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Fresenius Kabi is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2018/07/06 |
|---|
| 最后更新日期 | 2025/02/12 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/pemetrexed-fresenius-kabi-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-fresenius-kabi |
|---|